Atossa Therapeutics’ (ATOS) Buy Rating Reaffirmed at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $7.00 price target on the stock.

Other research analysts have also recently issued research reports about the company. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets raised their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Stock Performance

NASDAQ ATOS traded up $0.00 during trading hours on Thursday, hitting $0.86. 1,305,011 shares of the company traded hands, compared to its average volume of 804,963. Atossa Therapeutics has a twelve month low of $0.72 and a twelve month high of $2.31. The stock has a market capitalization of $107.68 million, a price-to-earnings ratio of -3.89 and a beta of 1.26. The business’s 50-day moving average is $1.04 and its 200-day moving average is $1.27.

Institutional Investors Weigh In On Atossa Therapeutics

Several large investors have recently modified their holdings of the company. SG Americas Securities LLC grew its position in shares of Atossa Therapeutics by 148.2% during the 4th quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock worth $98,000 after buying an additional 62,016 shares during the period. JPMorgan Chase & Co. boosted its position in Atossa Therapeutics by 177.1% in the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock worth $227,000 after purchasing an additional 95,643 shares during the last quarter. Barclays PLC lifted its stake in Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after purchasing an additional 123,683 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after purchasing an additional 44,762 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in Atossa Therapeutics by 101.2% in the third quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after purchasing an additional 24,951 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.